Melanoma is the deadliest form of skin cancer, but it's also one of the most curable — if caught early. A thin melanoma (less than 1mm deep) has a 5-year melanoma-specific survival rate above 95%. For a thick, ulcerated one (over 4mm), it falls to about 82% even before it has spread to the lymph nodes — and lower once it has. Much of the difference between these outcomes is timing — and the quality of the tool used to look.
The naked-eye problem
A standard skin check — a physician looking at your moles with the naked eye — has a sensitivity for melanoma of roughly 76% in pooled studies. That means about one in four melanomas is missed on visual inspection alone. For non-specialist physicians (primary care doctors doing a quick "skin check" during an annual physical), the sensitivity may be even lower.
The reason is that early melanomas can look deceptively normal. The ABCDE criteria (asymmetry, border irregularity, color variation, diameter >6mm, evolution) are useful for patient self-screening, but they miss small, amelanotic (non-pigmented), and nodular melanomas — which are often the most aggressive types.
What dermatoscopy adds
Dermatoscopy (also called dermoscopy) uses a handheld device with polarized light and magnification to see structures beneath the skin surface that are invisible to the naked eye. It's the equivalent of giving the examiner a 10x microscope for every lesion.
The evidence is consistent: a 2008 meta-analysis of 9 studies in clinical settings found dermatoscopy clearly more accurate than naked-eye examination. A 2018 Cochrane review of in-person examinations estimated sensitivity at about 92% with dermatoscopy compared to 76% for the naked eye. Importantly, it also improves specificity (about 95% vs 75% in the same review) — meaning fewer benign lesions are unnecessarily removed.
Digital dermatoscopy adds another layer: standardized photographic documentation of every lesion, allowing comparison over time. A mole that looks unchanged to the eye may show subtle structural changes under dermatoscopy that signal early malignant transformation.
A screening not limited to high-risk groups
Unlike most screenings discussed in this journal, a skin examination is relevant beyond clearly defined high-risk groups. Melanoma can occur in young, low-risk individuals with no family history. Fair skin and high UV exposure increase risk, but they're not prerequisites. For this reason, full-body dermatoscopy is one of the few tests for which a case for broad screening is commonly made. It should be said, however, that randomized evidence that population screening reduces melanoma deaths is lacking: the US Preventive Services Task Force (2023) rates the evidence as insufficient. The case for dermatoscopy rests on better diagnostic accuracy, not on proven mortality benefit.
What happens if something is found
If a dermatoscopic examination identifies a suspicious lesion, the usual next step is an excisional biopsy under local anesthesia, often during the same visit or shortly afterwards. The specimen is sent for histopathology; ask when to expect the result, as turnaround times vary.
If a melanoma or other skin cancer is confirmed, a good process includes complete pathology staging and, where indicated, referral to dermatologic surgery or oncology. It is reasonable to ask in advance how results will be communicated, who coordinates the next steps, and how follow-up examinations will be organized — and to discuss with your dermatologist how often you should be checked.
References
- Vestergaard ME, Macaskill P, Holt PE, Menzies SW. Dermoscopy compared with naked eye examination for the diagnosis of primary melanoma: a meta-analysis of studies performed in a clinical setting. Br J Dermatol. 2008;159(3):669-676. PMID: 18616769.
- Leitlinienprogramm Onkologie (DKG, DKH, AWMF). S3-Leitlinie Diagnostik, Therapie und Nachsorge des Melanoms. Version 3.3, Juli 2020. AWMF-Registernummer 032/024OL.
- Kittler H, et al. Diagnostic accuracy of dermoscopy. Lancet Oncol. 2002;3(3):159-165.
- Dinnes J, et al. Dermoscopy, with and without visual inspection, for diagnosing melanoma in adults. Cochrane Database Syst Rev. 2018;12:CD011902. doi:10.1002/14651858.CD011902.pub2.
- Gershenwald JE, et al. Melanoma staging: evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin. 2017;67(6):472-492.
- US Preventive Services Task Force. Screening for skin cancer: US Preventive Services Task Force recommendation statement. JAMA. 2023. doi:10.1001/jama.2023.4342.
This article is general information and not individual medical advice. Decisions about tests and treatment belong in a conversation with your own physician.